...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

BREAKING: TransCanna Receives State-Wide Operating License

  • Now owns largest known fully licensed cannabis facilities in California
  • Successfully granted a Type 11 'Distributor' license by the California Bureau of Cannabis Control for its 196,000 square foot Daly Avenue Facility
  • This long-anticipated milestone marks the completion of all state and local licenses required for the Company to begin operations at its flagship cannabis processing facility in Modesto, California

Transcanna dark

Hub On AGORACOM / Read Release

Message: Baricitinib restrains the immune dysregulation in COVID 19 patients

This drug seems to mitigate the same pro-inflammatory markers that Apabetalone does.  It is a JAK1/JAK2 inhibitor.  I can't recall, is RVX 208 also a JAK1/JAK2 inhibitor??

 

https://www.medrxiv.org/content/10.1101/2020.06.26.20135319v2.full.pdf+html

 

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing pandemic coronavirus disease 2019 (COVID-19). The majority of patients with COVID-19 have a good prognosis, but variable percentages in different countries develop pneumonia associated with lymphocytopenia and severe inflammatory response due to uncontrolled release of cytokines. These immune mediators are transcriptionally regulated by JAK-STAT molecular pathways, which can be disabled by small molecules. Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19. Indeed, we demonstrate a significant reduction in serum levels of interleukin (IL)-6, IL-1β and tumor necrosis factor (TNF), a rapid recovery in circulating T and B cell frequencies and an increased antibody production against SARS-CoV-2 spike protein in baricitinib-treated patients. Moreover, treated patients underwent a rapid reduction in oxygen flow need and progressive increase in the P/F. Our work provides the basis on developing effective treatments against COVID-19 pathogenesis using on-target therapy. 

 

This drug seemed to provide some real therapeutic benefit to patients suffering from severe acute respiratory distress syndrome

Share
New Message
Please login to post a reply